Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: VX-950 Clear all
Terminated Phase 3 Interventional Results available

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

NCT01821963
View directory record Official record
Conditions
Infection
Interventions
Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 21, 2026, 6:35 AM EDT
Withdrawn Phase 4 Interventional

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

NCT01415141
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon alfa-2a, Ribavirin, telaprevir
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

NCT00983853
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 21, 2026, 6:35 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

NCT01532908
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2)
Biological · Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

NCT01598090
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Telaprevir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

NCT01054573
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Coronado, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated interferon alfa 2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

NCT01355289
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Sep 21, 2026, 6:35 AM EDT
Completed No phase listed Observational

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02452814
View directory record Official record
Conditions
HCV
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 21, 2026, 6:35 AM EDT
Terminated Phase 4 Interventional Results available

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

NCT01467492
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

NCT01563328
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, BCV, TVR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

NCT01786382
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668, Midazolam, Omeprazole, Telaprevir
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

NCT00262483
View directory record Official record
Conditions
Hepatitis C
Interventions
VX-950, ribavirin, peginterferon alfa-2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging of GSK2336805 in Combination Therapy

NCT01648140
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

NCT01994486
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir and Sofosbuvir
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 1 Interventional

Study of Telaprevir in Subjects With Hepatic Impairment

NCT00509210
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
telaprevir (VX-950)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2008 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir, ribavirin, peginterferon alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 21, 2026, 6:35 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

NCT01459913
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 21, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 21, 2026, 6:35 AM EDT
Withdrawn No phase listed Observational

SIMpill Medication Dispensing Device in the Treatment of HCV

NCT01691235
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
SIMpill device
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 21, 2026, 6:35 AM EDT